Long-term safety of ketamine and esketamine in treatment of depression

Nikayin, S; Murphy, E; Krystal, JH; Wilkinson, ST

Wilkinson, ST (通讯作者),Yale Sch Med, Dept Psychiat, Yale Depress Res Program, 100 York St,STE 2J, New Haven, CT 06511 USA.

EXPERT OPINION ON DRUG SAFETY, 2022; 21 (6): 777

Abstract

Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by th......

Full Text Link